Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387205 · ClinicalTrials.gov registry record · Phase 1
Study To Assess Long Term Safety Of Pazopanib
A Phase 1 study of Carcinoma, Renal Cell, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
- 19
- Study locations
NCT00387205 is a Phase 1 study of Carcinoma, Renal Cell that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 188 participants, below the 278-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (32% lower). The trial reports 19 study locations across 16 states.
The verdict
NCT00387205, a Phase 1 study of Carcinoma, Renal Cell, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.
Conditions Studied
Interventions
- DRUG Pazopanib
Study Locations (19)
Other
- Novartis Investigative Site - Lyon
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Newcastle upon Tyne
California
- Novartis Investigative Site - Duarte
- Novartis Investigative Site - Santa Monica
Colorado
- Novartis Investigative Site - Aurora
Indiana
- Novartis Investigative Site - Indianapolis
Michigan
- Novartis Investigative Site - Detroit
Minnesota
- Novartis Investigative Site - Minneapolis
New Hampshire
- Novartis Investigative Site - Lebanon
New Jersey
- Novartis Investigative Site - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2006-06-20 |
| Est. Completion | 2018-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387205
The ClinicalTrials.gov registry entry for NCT00387205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 278-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (32% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Pazopanib is the first listed.
NCT00387205 reports 19 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00387205 about?
NCT00387205 is a clinical study titled "Study To Assess Long Term Safety Of Pazopanib". This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.
What is the current status of trial NCT00387205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2006-06-20. Estimated completion is 2018-03-08.
What conditions does trial NCT00387205 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00387205?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT00387205?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00387205 being conducted?
This trial has 19 study locations across California, Colorado, Indiana, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.